Roa-Bruzón Iliannis Y, Duany-Almira Luis F, Valle-Delgadillo Yeminia M, Flores-Salinas Héctor E, Valdés-Alvarado Emmanuel, Padilla-Gutiérrez Jorge R
Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Ciencias Biomédicas (IICB), Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.
Departamento de Biología Molecular y Genómica, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.
Cells. 2025 Apr 15;14(8):597. doi: 10.3390/cells14080597.
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the joints, limiting patients' mobility and quality of life. Recent studies have shown that patients with AS have a significantly higher risk of developing severe cardiovascular complications, such as acute coronary syndrome (ACS). A comprehensive review (2014-2024) included a study evaluating the significance of matrix metalloproteinase 3 (MMP-3) in cardiovascular risk among AS patients. The findings indicate that chronic inflammation in AS not only damages the joints but also contributes to the progression of cardiovascular diseases. At the molecular level, MMP-3 is instrumental in degrading the extracellular matrix, leading to instability in the atherosclerotic plaques and increasing the risk of ACS. Additionally, MMP-3 activation is related to the inflammatory pathways, such as tumor necrosis factor-alpha (TNF-α) and NF-κB, which amplify its effect on both joint destruction and vascular damage. This molecular approach offers new perspectives for understanding and treating AS and its cardiovascular complications, suggesting that MMP-3 inhibition could be a promising therapeutic strategy to mitigate cardiovascular risk in these patients.
强直性脊柱炎（AS）是一种主要影响关节的慢性炎症性疾病，会限制患者的活动能力和生活质量。最近的研究表明，AS患者发生严重心血管并发症（如急性冠状动脉综合征（ACS））的风险显著更高。一项全面综述（2014 - 2024年）纳入了一项评估基质金属蛋白酶3（MMP - 3）在AS患者心血管风险中的意义的研究。研究结果表明，AS中的慢性炎症不仅会损害关节，还会促进心血管疾病的进展。在分子水平上，MMP - 3有助于降解细胞外基质，导致动脉粥样硬化斑块不稳定，并增加ACS的风险。此外，MMP - 3的激活与炎症途径（如肿瘤坏死因子 - α（TNF - α）和核因子κB）有关，这些炎症途径会放大其对关节破坏和血管损伤的影响。这种分子方法为理解和治疗AS及其心血管并发症提供了新的视角，表明抑制MMP - 3可能是降低这些患者心血管风险的一种有前景的治疗策略。
